Novel synthetic curcumin analogues EF31 and UBS109 are potent DNA hypomethylating agents in pancreatic cancer

Cancer Letters

Volumn 341, Issue 2, 2013, Pages 195-203

  Nagaraju, Ganji Purnachandra ^a   Zhu, Shijun ^a   Wen, Jing ^a   Farris, Alton B ^a   Adsay, Volkan N ^a   Diaz, Roberto ^a   Snyder, James P ^b   Mamoru, Shoji ^a   El Rayes, Bassel F ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Curcumin; DNA methylation; EF31; Pancreatic cancer; UBS109

Indexed keywords

ANTINEOPLASTIC AGENT; CURCUMIN; CYTOSINE; DNA METHYLTRANSFERASE 1; EF 31; FLUOROURACIL; HEAT SHOCK PROTEIN 90; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEONECTIN; OXALIPLATIN; POLYPHENOL DERIVATIVE; PROTEIN P16; UBS 109; UNCLASSIFIED DRUG; UVOMORULIN; 3,5-BIS(2-PYRIDINYLMETHYLIDENE)-4-PIPERIDONE; CADHERIN; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; PIPERIDONE DERIVATIVE; SPARC PROTEIN, HUMAN; UBS109;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DEMETHYLATION; DNA METHYLATION; DOWN REGULATION; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SENSITIZATION; FEMALE; GENE EXPRESSION; GENE SILENCING; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANIMAL; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; NUDE MOUSE; PANCREATIC NEOPLASMS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CADHERINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CURCUMIN; CYTOSINE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; OSTEONECTIN; PANCREATIC NEOPLASMS; PIPERIDONES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84887183809     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.08.002     Document Type: Article

References (29)

1. Baylin S.B., Jones P.A. A decade of exploring the cancer epigenome - biological and translational implications. Nat. Rev. Cancer 2011, 11:726-734.
2. Robertson K.D. DNA methylation, methyltransferases, and cancer. Oncogene 2001, 20:3139-3155.
3. Taberlay P.C., Jones P.A. DNA methylation and cancer. Prog. Drug Res. 2011, 67:1-23.
4. Liu S., Liu Z., Xie Z., Pang J., Yu J., Lehmann E., et al. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood 2008, 111:2364-2373.
5. Zhou Q., Agoston A.T., Atadja P., Nelson W.G., Davidson N.E. Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells. Mol. Cancer Res. 2008, 6:873-883.
6. Zhang J.J., Zhu Y., Wu J.L., Liang W.B., Zhu R., Xu Z.K., et al. Association of increased DNA methyltransferase expression with carcinogenesis and poor prognosis in pancreatic ductal adenocarcinoma. Clin. Transl. Oncol. 2012, 14:116-124.
7. Ueki T., Toyota M., Skinner H., Walter K.M., Yeo C.J., Issa J.P., et al. Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma. Can. Res. 2001, 61:8540-8546.
8. Fukushima N., Sato N., Ueki T., Rosty C., Walter K.M., Wilentz R.E., et al. Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Am. J. Pathol. 2002, 160:1573-1581.
9. Sato N., Ueki T., Fukushima N., Iacobuzio-Donahue C.A., Yeo C.J., Cameron J.L., et al. Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology 2002, 123:365-372.
10. Sato N., Fukushima N., Maehara N., Matsubayashi H., Koopmann J., Su G.H., et al. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene 2003, 22:5021-5030.
11. Sato N., Fukushima N., Maitra A., Matsubayashi H., Yeo C.J., Cameron J.L., et al. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Can. Res. 2003, 63:3735-3742.
12. Fu S., Kurzrock R. Development of curcumin as an epigenetic agent. Cancer 2010, 116:4670-4676.
13. Kunnumakkara A.B., Guha S., Krishnan S., Diagaradjane P., Gelovani J., Aggarwal B.B. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Can. Res. 2007, 67:3853-3861.
14. Gerhauser C. Cancer chemoprevention and nutriepigenetics: state of the art and future challenges. Top. Curr. Chem. 2013, 329:73-132.
15. Liu Z., Xie Z., Jones W., Pavlovicz R.E., Liu S., Yu J., et al. Curcumin is a potent DNA hypomethylation agent. Bioorg. Med. Chem. Lett. 2009, 19:706-709.
16. Adams B.K., Ferstl E.M., Davis M.C., Herold M., Kurtkaya S., Camalier R.F., et al. Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. Bioorg. Med. Chem. Lett. 2004, 12:3871-3883.
17. Zhu S., Moore T.W., Lin X., Morii N., Mancini A., Howard R.B., Culver D., et al. Synthetic curcumin analog EF31 inhibits the growth of head and neck squamous cell carcinoma xenografts. Integr. Biol. (Cambridge) 2012, 4:633-640.
18. Nagaraju G.P., El-Rayes B.F. SPARC and DNA methylation: possible diagnostic and therapeutic implications in gastrointestinal cancers. Can. Lett. 2013, 328:10-17.
19. Wang W., Abbruzzese J.L., Evans D.B., Larry L., Cleary K.R., Chiao P.J. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin. Cancer Res. 1999, 5:119-127.
20. Kanda M., Matthaei H., Wu J., Hong S.M., Yu J., Borges M., et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology 2012, 142:730-739.
21. Aguirre A.J., Bardeesy N., Sinha M., Lopez L., Tuveson D.A., Horner J., et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 2003, 17:3112-3126.
22. Bartsch D.K., Sina-Frey M., Lang S., Wild A., Gerdes B., Barth P., et al. CDKN2A germline mutations in familial pancreatic cancer. Ann. Surg. 2002, 236:730-737.
23. Adams B.K., Cai J., Armstrong J., Herold M., Lu Y.J., et al. EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism. Anticancer Drugs 2005, 16:263-275.
24. Gao J., Song J., Huang H., Li Z., Du Y., Cao J., et al. Methylation of the SPARC gene promoter and its clinical implication in pancreatic cancer. J. Exp. Clin. Can. Res. 2010, 29:28.
25. Rahman M., Chan A.P., Tai I.T. A peptide of SPARC interferes with the interaction between caspase8 and Bcl2 to resensitize chemoresistant tumors and enhance their regression in vivo. PLoS ONE 2011, 6:e26390.
26. Yiu G.K., Chan W.Y., Ng S.W., Chan P.S., Cheung K.K., Berkowitz R.S., et al. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am. J. Pathol. 2001, 159:609-622.
27. Tang M.J., Tai I.T. A novel interaction between procaspase 8 and SPARC enhances apoptosis and potentiates chemotherapy sensitivity in colorectal cancers. J. Biol. Chem. 2007, 282:34457-34467.
28. von Burstin J., Eser S., Paul M.C., Seidler B., Brandl M., Messer M., et al. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology 2009, 137:361-371.
29. Dhillon N., Aggarwal B.B., Newman R.A., Wolff R.A., Kunnumakkara A.B., Abbruzzese J.L., et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res. 2008, 14:4491-4499.